Xencor (XNCR) Share-based Compensation (2013 - 2026)
Xencor (XNCR) posted quarterly Share-based Compensation of $9.6 million for Q1 2026, down 21.71% year-over-year from $12.2 million in Q1 2025, and down 6.13% quarter-over-quarter from $10.2 million in Q4 2025.
Xencor (XNCR) Share-based Compensation (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Share-based Compensation for 14 consecutive years, with $9.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 21.71% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at $40.6 million (down 24.96% YoY), while the FY2025 annual figure was $43.2 million, down 18.87% from the prior year.
- Share-based Compensation eased to $9.6 million in Q1 2026 per XNCR's latest filing, from $10.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $51.3 million in Q4 2023 and bottomed at -$30.0 million in Q4 2022.
- Historically, Share-based Compensation has averaged $11.9 million across 5 years, with a median of $12.3 million in 2024.
- On a YoY basis, Share-based Compensation climbed as much as 1295.68% in 2022 and fell as far as 1082.08% in 2022.
- Xencor's Share-based Compensation stood at -$30.0 million in 2022, then soared by 270.9% to $51.3 million in 2023, then sank by 75.96% to $12.3 million in 2024, then declined by 17.41% to $10.2 million in 2025, then slipped by 6.13% to $9.6 million in 2026.
- Business Quant data shows XNCR's Share-based Compensation at $9.6 million in Q1 2026, $10.2 million in Q4 2025, and $10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 9.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.19 Mn |
| Jun 30, 2026 | 9.19 Mn |
| Mar 31, 2026 | 9.56 Mn |
| Mar 31, 2026 | 9.56 Mn |
| Dec 31, 2025 | 10.19 Mn |
| Dec 31, 2025 | 10.19 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Mar 31, 2025 | 12.21 Mn |
| Mar 31, 2025 | 12.21 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Sep 30, 2024 | 12.34 Mn |
| Sep 30, 2024 | 12.34 Mn |
| Jun 30, 2024 | 17.19 Mn |
| Jun 30, 2024 | 17.19 Mn |
| Mar 31, 2024 | 11.42 Mn |
| Mar 31, 2024 | 11.42 Mn |